282 related articles for article (PubMed ID: 25500488)
1. Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans.
Storka A; Vcelar B; Klickovic U; Gouya G; Weisshaar S; Aschauer S; Bolger G; Helson L; Wolzt M
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):54-65. PubMed ID: 25500488
[TBL] [Abstract][Full Text] [Related]
2. Effect of liposomal curcumin on red blood cells in vitro.
Storka A; Vcelar B; Klickovic U; Gouya G; Weisshaar S; Aschauer S; Helson L; Wolzt M
Anticancer Res; 2013 Sep; 33(9):3629-34. PubMed ID: 24023289
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals.
Bolger GT; Licollari A; Tan A; Greil R; Vcelar B; Greil-Ressler S; Weiss L; Schönlieb C; Magnes T; Radl B; Majeed M; Sordillo PP
Cancer Chemother Pharmacol; 2019 Feb; 83(2):265-275. PubMed ID: 30430227
[TBL] [Abstract][Full Text] [Related]
4. Infusion pharmacokinetics of Lipocurc™ (liposomal curcumin) and its metabolite tetrahydrocurcumin in Beagle dogs.
Helson L; Bolger G; Majeed M; Vcelar B; Pucaj K; Matabudul D
Anticancer Res; 2012 Oct; 32(10):4365-70. PubMed ID: 23060560
[TBL] [Abstract][Full Text] [Related]
5. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers.
Kanai M; Imaizumi A; Otsuka Y; Sasaki H; Hashiguchi M; Tsujiko K; Matsumoto S; Ishiguro H; Chiba T
Cancer Chemother Pharmacol; 2012 Jan; 69(1):65-70. PubMed ID: 21603867
[TBL] [Abstract][Full Text] [Related]
6. Tissue distribution of (Lipocurc™) liposomal curcumin and tetrahydrocurcumin following two- and eight-hour infusions in Beagle dogs.
Matabudul D; Pucaj K; Bolger G; Vcelar B; Majeed M; Helson L
Anticancer Res; 2012 Oct; 32(10):4359-64. PubMed ID: 23060559
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc
Greil R; Greil-Ressler S; Weiss L; Schönlieb C; Magnes T; Radl B; Bolger GT; Vcelar B; Sordillo PP
Cancer Chemother Pharmacol; 2018 Oct; 82(4):695-706. PubMed ID: 30074076
[TBL] [Abstract][Full Text] [Related]
8. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
Mach CM; Mathew L; Mosley SA; Kurzrock R; Smith JA
Anticancer Res; 2009 Jun; 29(6):1895-9. PubMed ID: 19528445
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients.
Bedikian AY; Vardeleon A; Smith T; Campbell S; Namdari R
J Clin Pharmacol; 2006 Jul; 46(7):727-37. PubMed ID: 16809798
[TBL] [Abstract][Full Text] [Related]
10. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
12. Distribution and Metabolism of Lipocurc™ (Liposomal Curcumin) in Dog and Human Blood Cells: Species Selectivity and Pharmacokinetic Relevance.
Bolger GT; Licollari A; Tan A; Greil R; Vcelar B; Majeed M; Helson L
Anticancer Res; 2017 Jul; 37(7):3483-3492. PubMed ID: 28668837
[TBL] [Abstract][Full Text] [Related]
13. Clevidipine: a review of its use in the management of acute hypertension.
Deeks ED; Keating GM; Keam SJ
Am J Cardiovasc Drugs; 2009; 9(2):117-34. PubMed ID: 19331440
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
15. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients.
Kanai M; Otsuka Y; Otsuka K; Sato M; Nishimura T; Mori Y; Kawaguchi M; Hatano E; Kodama Y; Matsumoto S; Murakami Y; Imaizumi A; Chiba T; Nishihira J; Shibata H
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1521-30. PubMed ID: 23543271
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
17. Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human Volunteers.
Asher GN; Xie Y; Moaddel R; Sanghvi M; Dossou KS; Kashuba AD; Sandler RS; Hawke RL
J Clin Pharmacol; 2017 Feb; 57(2):185-193. PubMed ID: 27503249
[TBL] [Abstract][Full Text] [Related]
18. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
20. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
